Aether Industries Ltd
Aether Industries Ltd Q4 FY26 Results & Concall Highlights: Revenue, Margins & Order Book
Q4 FY26 earnings call: what management guided on revenue, margins and order book.
The short version
Targeting 70% revenue from CRAMS and CEM and around 30% from Large Scale Manufacturing (LSM) in the next couple of years. Revenue growth expected from commercialization and ramp-up of Site 5, Site 3++, and Site 4, with strong contributions from CEM and CRAMS segments.
From Aether Industries Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Targeting 70% revenue from CRAMS and CEM and around 30% from Large Scale Manufacturing (LSM) in the next couple of years.
- Major growth drivers in FY27 include commercialization of Site 5 Phase 1 and ramp-up of Site 3++ and Site 4.
- Expect sustained elevated prices in LSM for next 2-3 quarters, supporting stable/strong revenues.
- Site 5 to commercialize three new LSM products priced at $30-$40/kg, expected to contribute meaningfully from FY27.
- Anticipate revenue growth from existing marquee customers like Milliken and Baker Hughes, supplemented by new projects and sites.
- Working capital improvements expected, with days reduced toward ~160 by FY27 end, supporting operational efficiency.
- Capex of INR1,500-1,600 crore over next 4 years focused on expanding manufacturing and R&D capabilities for sustained growth.
- No explicit revenue growth guidance given, but accelerating adoption of new chemistries and production blocks indicates positive volume momentum.
Profitability & Margins
See what Aether Industries Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- FY26 capex was INR 383.8 crores; FY27 capex expected between INR 300-350 crores, primarily for Site 5 and new R&D site.
- Total remaining capex across announced 3 sites is approximately INR 1500-1600 crores over the next 4 years.
- Major capex focus: Site 5 commercialization and expansion, Site 1 R&D expansion.
- Site 5 planned for up to 20 production blocks over ~45-46 acres including newly acquired adjoining land.
- Investment in expanded world-class R&D infrastructure including large pilot plants and 18 new fume hoods.
- Site 5’s asset turn target is 1.5 to 1.75.
- Capex and R&D investments aimed to drive transition to 70% revenue from CRAMS and CEM models by FY30.
- Additional debt of INR 200-250 crores expected in FY27 to support capex.
- Expansion of senior leadership team focused on technology and business development to capitalize on opportunities.
Top-ranked in Chemicals & Petrochemicals
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Aether Industries Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The transcript does not explicitly mention the exact value or volume of the current or expected order book or pending orders.
- It highlights strong order inflows with a focus on new large-scale manufacturing products at Site 5, with validation batches done and orders already in hand for 3 new products expected by May end or early June.
- The company has completed over 50 customer and certification audits and added 19 new marquee clients recently.
- Multiple customers have completed pre-audits for Site 5, indicating strong customer qualification activity and future order potential.
- The focus is on converting opportunities into execution with a growing customer base and expanding capacity at multiple sites.
- Continuous order inflows from key customers such as Baker Hughes confirmed, with steady demand and no cancellations or delays mentioned.
- Overall, order momentum is strong with increasing mix from CRAMS and CEM contributing to anticipated growth.
Aether Industries Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹305 Cr, net profit ₹54 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Aether Industri.'s management said in earlier quarters
Others in Chemicals & Petrochemicals this season
- NOCIL Ltd (Q4 FY26)
The Rs.130 crores capex includes some intermediates and is largely for captive consumption, with part allocated to finished goods. Key concall takeaways from…
- Indo Borax & Ch. (Q4 FY26)
175 crores revenue in the previous financial year and Rs. Key concall takeaways from Indo Borax & Chemicals Ltd's Q4 FY26 earnings call — and how it ranks…
- Rossari Biotech Ltd (Q4 FY26)
50-70 crore planned for FY27 focused on pharma and aroma chemical facilities to support value-added product segments. Key concall takeaways from Rossari…
- Pidilite Inds. (Q4 FY26)
Underlying volume growth (UVG) averaged over 9% per quarter last year, with a ~200 bps increase in FY '25; the company plans to continue lifting UVG…
Frequently Asked Questions
What were Aether Industries Ltd Q4 FY26 results?
Targeting 70% revenue from CRAMS and CEM and around 30% from Large Scale Manufacturing (LSM) in the next couple of years. Revenue growth expected from commercialization and ramp-up of Site 5, Site 3++, and Site 4, with strong contributions from CEM and CRAMS segments.
What is Aether Industries Ltd share price analysis?
Aether Industries Ltd currently shows a neutral. The stock trades at a P/E of 87.9 with a market cap of ₹21,093 Cr. Investors should review the full earnings analysis for detailed insights.
Is Aether Industries Ltd planning capital expenditure?
FY26 capex was INR 383.8 crores; FY27 capex expected between INR 300-350 crores, primarily for Site 5 and new R&D site.
Keep Aether Industries Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.